Evaluation of Inflammatory Markers in ph Negative Myeloproliferative Neoplasms: Impact on
This study aims to observe inflammatory biomarkers and their trend over the history of the disease in patients suffering from MPN Ph negative; it also wants to identify any correlations between the aforementioned biomarkers and disease outcomes, considering first of all the occurrence of thrombo-haemorrhagic events and
| Condition(s) | Myeloproliferative Disease, Inflammatory Markers |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | This study aims to observe inflammatory biomarkers and their trend over the history of the disease in patients suffering from MPN Ph negative; it also wants to identify any correlations between the aforementioned biomarkers and disease outcomes, considering first of all the occurrence of thrombo-haemorrhagic events and the evolution in the accelerated / blast phase of the disease, shedding light on new tools that can potentially guarantee a prompt and better risk stratification |
| Who can participate | Inclusion Criteria: * Age ≥ 18 years at the time of diagnosis of MPN Ph negative * Diagnosis of PV, ET, PMF or post PV and post ET MF, according to current WHO or IWG-MRT criteria (diagnosis since 2000) * Obtaining informed consent Exclusion Criteria: * Life expectancy of less than 6 months * Accelerated phase myelofibrosis or MPN with signs of leukemic evolution |
| Ages | 18 Years to 99 Years |
| Sex | All |
| Lead sponsor | University of Milano Bicocca |
| Locations | Bari, Italy; Bologna, Italy; Brescia, Italy; Catania, Italy; Naples, Italy; Roma, Italy (+5 more sites) |
| Start date | 2022-09-08 |
| NCT ID | NCT05553873 |
| Official listing | https://clinicaltrials.gov/study/NCT05553873 |